A Randomized, Double-blind, Placebo-controlled Trial of DL-3-n-butylphthalide in Amyotrophic Lateral Sclerosis Patients
Mingsheng Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Liying Cui(Ansteel (China)), Huifang Shang(Sichuan University), Xiaoli Yao(Second Military Medical University), Jia He(Shanghai University of Medicine and Health Sciences), Xusheng Huang(Chinese PLA General Hospital), Dongsheng Fan(King University)
Cited by 0
Related Papers
Stroke in China: advances and challenges in epidemiology, prevention, and management
|The Lancet Neurology|2019|1.6k
Estimated Burden of Stroke in China in 2020
|JAMA Network Open|2023|595
China stroke surveillance report 2021
|Military Medical Research|2023|554
Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing
|Genome Medicine|2019|537
Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis
|Journal of Neurology|2019|315